HALO Strangle Strategy
HALO (Halozyme Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents.
HALO (Halozyme Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $8.89B, a trailing P/E of 25.39, a beta of 0.87 versus the broader market, a 52-week range of 51.06-82.22, average daily share volume of 1.7M, a public-listing history dating back to 2004, approximately 350 full-time employees. These structural characteristics shape how HALO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.87 places HALO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on HALO?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current HALO snapshot
As of June 30, 2026, spot at $78.28, ATM IV 35.10%, IV rank 4.88%, expected move 10.06%. The strangle on HALO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on HALO specifically: HALO IV at 35.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a HALO strangle, with a market-implied 1-standard-deviation move of approximately 10.06% (roughly $7.88 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HALO expiries trade a higher absolute premium for lower per-day decay. Position sizing on HALO should anchor to the underlying notional of $78.28 per share and to the trader's directional view on HALO stock.
HALO strangle setup
The HALO strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HALO near $78.28, the first option leg uses a $82.19 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HALO chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HALO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $82.19 | N/A |
| Buy 1 | Put | $74.37 | N/A |
HALO strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
HALO strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on HALO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on HALO
Strangles on HALO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the HALO chain.
HALO thesis for this strangle
The market-implied 1-standard-deviation range for HALO extends from approximately $70.40 on the downside to $86.16 on the upside. A HALO long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current HALO IV rank near 4.88% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on HALO at 35.10%. As a Healthcare name, HALO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HALO-specific events.
HALO strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HALO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HALO alongside the broader basket even when HALO-specific fundamentals are unchanged. Always rebuild the position from current HALO chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on HALO?
- A strangle on HALO is the strangle strategy applied to HALO (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With HALO stock trading near $78.28, the strikes shown on this page are snapped to the nearest listed HALO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are HALO strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the HALO strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 35.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a HALO strangle?
- The breakeven for the HALO strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current HALO market-implied 1-standard-deviation expected move is approximately 10.06%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on HALO?
- Strangles on HALO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the HALO chain.
- How does current HALO implied volatility affect this strangle?
- HALO ATM IV is at 35.10% with IV rank near 4.88%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.